DEA proposes easing restrictions on Schedule II drugs
"We listened to the comments of more than 600 physicians, pharmacists, nurses, patients, and advocates for pain treatment and studied their concerns carefully," explained DEA administrator Karen P. Tandy in a written statement. "The policy statement reiterates DEA's commitment to striking the proper balance to ensure that people who need pain relief get it, and those who abuse it, don't."
The proposed change is designed to make it easier for patients with chronic pain to avoid multiple doctor visits. Physicians will be permitted to prescribe up to a 90-day supply of Schedule II drugs during a single office visit, when medically appropriate. Doctors can write a single prescription or multiple Rxs, as long as the total does not exceed a 90-day supply. The Controlled Substances Act (CSA) does not permit refills.
The changes came about as a result of a concerted effort by pharmacists and doctors to clarify the DEA position. "We are extremely pleased with the turn of events," said Kevin Nicholson, R.Ph., J.D., VP of pharmacy regulatory affairs at the National Association of Chain Drug Stores. "We're glad DEA recognizes that the earlier rules were an unnecessary inconvenience. In some ways, these rule changes will provide more oversight over patients."
The American Medical Association was also pleased with the new rule. "Relieving suffering while doing everything we can to prevent the abuse of controlled substances reflects appropriate patient care, a standard that's easier to achieve when a strong patient-physician relationship exists," explained Rebecca J. Patchin, M.D., an AMA board member, in a written response to the new rule.
The new rule is the result of a long, slow process to update the existing rules governing Schedule II drugs. In September 2001, the agency committed itself to a "balanced policy," which aimed to give equal measure to both the enforcement of abuses and the legal use of controlled substances. In February 2004, DEA issued an interim statement and invited feedback.
The challenge has been to control nonmedical uses of controlled substances without adversely impacting patients with true medical need. Abuse of Rx drugs appears to be a growing trend. According to the recent National Survey on Drug Use and Health by the Department of Health & Human Services, prescription drugs are now the second-most commonly abused drugs, behind only marijuana. In 2004, the survey noted, 2.4 million people used Rx drugs for nonmedical reasons. In another study, by the University of Michigan, in 2005 9.5% of 12th graders reported using Vicodin (acetaminophen; hydrocodone bitartrate, Abbott) during the previous year and 5.5% reported using oxycodone during the same period.
One of the side effects of the increased misuse of Rx drugs has been a tendency to underprescribe controlled substances. In 2004, the Federation of State Medical Boards of the United States noted that a significant body of evidence suggests that "both acute and chronic pain continue to be undertreated." The group attributed the problem to a lack of knowledge of medical standards, current research, and clinical guidelines for appropriate pain treatment; fear of undue scrutiny by regulatory authorities; misunderstanding of addiction and dependence; and a lack of understanding of regulatory policies and processes.
In its statement, DEA noted that it would not indicate when prescribing controlled substances was and was not medically appropriate. The agency noted that its authority under the CSA is "equivalent to that of a state medical board" and that the agency "does regulate the general practice of medicine."
MORE ARTICLES IN THIS ISSUE
Invasive fungal infections will have less of a fighting chance now that a new antifungal has been approved by the Food & Drug Administration. Posaconazole (Noxafil, Schering-Plough), available as an oral suspension, is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age and older who are immunocompromised, such as hematopoietic stem cell transplant recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy.
More than 8,000 prescriptions electronically filed in the eRx Collaborative system were changed this June as a result of drug-drug or drug-allergy alerts. The eRx Collaborative initiative is a consortium created by Blue Cross Blue Shield of Massachusetts, Tufts Health Plan, and Neighborhood Health Plan to spur e-prescribing in the state. It includes 3,400 prescribers. The 8,000 prescriptions represented 2% of the approximately 400,000 total electronic Rxs filed in June. In fact, as a recent study from the Medical Records Institute noted, avoiding drug allergy was the prime use for e-prescribing, followed closely by access to drug reference information.
From pills to patches, from implants to Plan B going OTC, women have more contraceptives to choose from today than ever before.
I want to respond to your Sept. 4 cover story on franchising. In January of 2003, my husband and I purchased a Medicap store grossing $2.2 million. Gross profit margins were 25%-30%. Paying franchise royalties was a bite, but manageable. My customer base was 80%-90% cash-paying seniors over 65. In May 2005 we opened a second store. It did incredibly well for a new store, and being part of a franchise was a big help in getting a new store open. But everything changed in January 2006, when Part D hit. My two stores together took a net loss of $120,000 during the first two months of Part D. I had royalties to pay and a high debt load because both of my stores were still new, and by Aug 11, 2006, both my stores were closed.